Our Company
Xanamem^®
Clinical Trials
Investor Centre
News
Contact Us

BACK TO NEWS

Therese Russell • 09 Dec 2022

Edison Investment Research Flash Note
XanaCIDD study in MDD underway

Enjoyed this read?

Stay up to date with our latest research.

Related articles

Corporate Presentations

Webcast Video Recording: Actinogen updated Depression Trial results and implications presentation

Actinogen • August 30, 2024

Press Releases and Media

Actinogen announces further positive results on depression in the XanCIDD phase 2a trial

PR Newswire • August 26, 2024

Corporate Presentations

Webcast Video Recording: Actinogen XanaCIDD topline results presentation

Actinogen • August 12, 2024

Our Company
Xanamem^®

Clinical Trials

Investors
News
Contact Us
Target Market Determination

Copyright © 2024 Actinogen